Real-life Experience of Bimekizumab in 27 Obese Patients With Plaque-type Psoriasis: a 24-week Multicenter Retrospective Study

Real-life Experience of Bimekizumab in 27 Obese Patients With Plaque-type Psoriasis: a 24-week Multicenter Retrospective Study

Authors

  • Zeno Fratton Institute of Dermatology, Department of Medicine, University of Udine, Italy
  • Vincenzo Maione Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy
  • Stefano Bighetti Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy
  • Luca Bettolini Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy
  • Giuseppe Stinco Institute of Dermatology, Department of Medicine, University of Udine, Italy
  • Enzo Errichetti Institute of Dermatology, Department of Medicine, University of Udine, Italy

Keywords:

obese, bimekizumab, psoriasis, safety, biologic

References

Megna M, Di Costanzo L, Argenziano, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19:855–861. DOI: 10.1080/14712598.2019.1622678. PMID: 31140882.

Gargiulo L, Ibba L, Malagoli P, et al. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1196966. DOI: 10.3389/fmed.2023.1196966. PMID: 37469659.

Galluzzo M, Marcelli L, Vellucci L, et al. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks. Expert Opin Biol Ther. 2023;23:371–381. DOI: 10.1080/14712598.2023.2194485. PMID: 36971507.

Mastorino L, Susca S, Megna M, et al. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther. 2022;35. DOI: 10.1111/dth.15378. PMID: 35156278.

Wang J, Yu Y, Liu L, et al. Global prevalence of obesity in patients with psoriasis: An analysis in the past two decades. Autoimmun Rev. 2024 Jun;23(6):103577. DOI: 10.1016/j.autrev.2024.103577. PMID: 39009055.

Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1243843. DOI: 10.3389/fmed.2023.1243843. PMID: 37614958.

Downloads

Published

2025-01-29

How to Cite

1.
Fratton Z, Maione V, Bighetti S, Bettolini L, Stinco G, Errichetti E. Real-life Experience of Bimekizumab in 27 Obese Patients With Plaque-type Psoriasis: a 24-week Multicenter Retrospective Study. Dermatol Pract Concept. 2025;15(1):4893. doi:10.5826/dpc.1501a4893

Share